For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development expenses | 63,797 | 74,091 | ||
| General and administrative | 45,460 | 31,675 | ||
| Total operating expenses | 109,257 | 105,766 | ||
| Operating loss | -109,257 | -105,766 | ||
| Gain on long-term investment | 3,390 | - | ||
| Accretion of discount on investments | - | 23 | ||
| Other expense, net | -18 | -9 | ||
| Interest expense | 95 | 137 | ||
| Interest income | 6,130 | 7,556 | ||
| (amortization of premium) accretion of discount on investments in u.s. treasury securities, net | -111 | - | ||
| Total other income and expense | 9,296 | 7,433 | ||
| Loss from operations before income taxes | -99,961 | -98,333 | ||
| Net loss | -99,961 | -98,333 | ||
| Basic EPS | -1.86 | -3.09 | ||
| Diluted EPS | -1.86 | -3.09 | ||
| Basic Average Shares | 53,645,323 | 31,787,491 | ||
| Diluted Average Shares | 53,645,323 | 31,787,491 | ||
Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics, Inc. (LXEO)